Compare Abbott Laboratories (ABT) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs FuelCell Energy Inc — how do they compare? Abbott Laboratories trades at $110.2 (market cap $187.95B), while FuelCell Energy Inc trades at $21.15 (market cap $1.54B). The key difference: Abbott Laboratories is far larger — about 122× FuelCell Energy Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| ABT | FCEL | |
|---|---|---|
Market Cap | $187.95B | $1.54B |
Sector | Health | Industrials |
52-Week High | $136.62 | $36.01 |
52-Week Low | $82.57 | $3.92 |
Enterprise Value | $214.96B | $1.38B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
FuelCell Energy (FCEL) trades at $19.83, down 2.94% on the day, with a bearish technical signal and negative profitability metrics. The company reported a net loss of $187.90 million on $158.16 million revenue for 2025, though it beat EPS estimates in two recent quarters. Recent news highlights partnerships with Siemens and AI-driven power demand opportunities, contributing to volatile stock performance.
Outlook remains speculative with high risk due to persistent losses and negative margins, offset by analyst optimism (45% buy rating) and a $20.75 consensus price target. Key risks include cash burn, competitive pressures, and execution challenges in scaling hydrogen technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
